PBRM1 and neoplasm: Our observations are consistent with recent reports demonstrating that inactivating mutations of the core components, e.g., PBRM1 of the PBAF complex, that are antagonistic to the PRC2 complex in tumor cells enhanced IFN-γ signaling and sensitized the PBAF-deficient tumors to ICB therapies (62, 63).